OKYO Pharma Limited
OKYOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. With a market capitalization of $80.3M, it sits in micro-cap territory. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Market Cap
$80.3M
Beta
0.00
P/E (TTM)
—
P/E (Fwd)
-2.32
EPS (TTM)
$-0.24
EPS (Fwd)
$-0.66
ROE
-263.8%
ROA
-43.1%
Cash
$20.6M
Total Debt
$0
Free CF
-$2.1M
52W Change
-28.0%
Annual Financials
Cash vs Debt
Where OKYO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, OKYO finished 0.61% below its 150-day moving average ($1.63) and 7.95% below its 200-day moving average ($1.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OKYO overbought or oversold?
At the September 3, 2026 close, OKYO's RSI(14) was 60.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
OKYO Pharma Limited reports $20.6M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$2.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -263.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, OKYO Pharma Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing OKYO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.